$3M Gene Therapy—With a Catch - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

$3M Gene Therapy—With a Catch

Medicaid is testing a pay-for-performance deal that makes drugmakers refund millions if new sickle cell gene therapies fail.

  • By

  • Phil Galewitz

  • January 21, 2026

  • 8 min

Share

Original Source(s)

$3M Gene Therapy—With a Catch

  • by Phil Galewitz

  • January 21, 2026

Related Content

Breastfeeding May Help Infants Achieve Adequate Sleep

A nationwide birth cohort found lower odds of short sleep at 1 year among infants breastfed during the first 6 months of life, regardless of formula supplementation.

FDA Monthly Preview: Key August Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.

Can Belzutifan Improve Adjuvant Therapy?

The phase 3 LITESPARK-022 trial compared adjuvant pembrolizumab plus belzutifan with pembrolizumab plus placebo following resection of clear-cell renal-cell carcinoma.